Fallopian Tube Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The fallopian tube cancer market size is expected to increase from USD 1.48 billion in 2025 to USD 1.59 billion in 2026 and reach USD 2.32 billion by 2031, growing at a CAGR of 7.76% over 2026-2031. This report is segmented by Offering (Treatment [Surgery, Chemotherapy, and More], Diagnosis), Disease Stage (Stage I-IV), Histology (High-Grade Serous, Low-Grade Serous, Endometrioid, Clear Cell, Mucinous, Carcinosarcoma), End User (Hospitals, Specialty Centers, Specialty Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Fallopian Tube Cancer Market Trends and Insights

Increasing Use of Antibody-Drug Conjugates

The U.S. Food and Drug Administration gave full approval to mirvetuximab soravtansine on March 22, 2024, for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer. The MIRASOL Phase 3 trial reported median overall survival of 16.5 months with mirvetuximab soravtansine and 12.7 months with chemotherapy, with a hazard ratio of 0.67 and a p-value of 0.0046. The trial also reported an objective response rate of 42% for the drug and 16% for chemotherapy. AbbVie received a positive CHMP opinion for ELAHERE in September 2024, supporting a route to broader European access. Daiichi Sankyo and AstraZeneca dosed the first patient in the DESTINY-Ovarian01 Phase 3 trial in December 2025, studying trastuzumab deruxtecan plus bevacizumab as first-line maintenance for HER2-expressing epithelial ovarian cancer, which includes fallopian tube cancer. The fallopian tube cancer market could therefore see treatment spending shift toward targeted regimens as these programs move through clinical development, especially when first-line maintenance studies establish an earlier role for antibody-drug conjugates and extend their use beyond the platinum-resistant setting. The pipeline also includes agents directed at TROP-2, NaPi2b, and B7-H4, which are being studied in trials that recruit patients with fallopian tube cancer. These programs seek to serve patients whose tumors are not suited to FRα-directed treatment, expanding the range of targets under evaluation.

Rising Biomarker-Guided Treatment Adoption

Biomarker selection has become part of routine treatment planning for many patients with epithelial ovarian and fallopian tube cancers. The ASCO guideline recommends germline sequencing of BRCA1 and BRCA2 through a multigene panel at diagnosis for all patients with epithelial ovarian cancer, including fallopian tube cancer. CMS Quality Measure #507 calls for germline genetic testing within 6 months of a fallopian tube cancer diagnosis as part of physician performance assessment. The NCCN framework also supports mirvetuximab soravtansine for appropriate patients with platinum-resistant disease and high FRα expression. These requirements make companion diagnostics important to access and prescribing, rather than a separate step after treatment selection. Better patient classification can also make clinical trial enrollment more precise, create more useful data for later targeted therapy programs, and support diagnosis growth within the fallopian tube cancer market as molecular results guide treatment eligibility. This feedback loop connects laboratory testing, treatment selection, and clinical development, rather than treating each activity as an isolated part of care.

Low Disease Awareness and Delayed Diagnosis

Fallopian tube carcinoma is difficult to identify before surgery because its symptoms can resemble ovarian tumors, adnexal masses, and benign pelvic disease. This uncertainty may delay therapeutic intervention and lead to diagnosis after the disease has advanced. There is no reliable population screening test for fallopian tube cancer, which limits the ability to detect microscopic disease at an early stage. The lack of a standard early detection pathway can restrict curative-intent surgery volumes and leave more patients needing complex treatment. Provider misconceptions about the need for universal testing also remain a barrier to consistent genetic testing in community oncology settings. The fallopian tube cancer market is affected when patients reach specialized services late or do not receive the testing that could identify therapy options.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of PARP Inhibitor Maintenance Therapy
• Greater Integration of Genetic and Molecular Testing
• High Cost of Long-Term Precision Oncology

Segment Analysis

Treatment accounted for 68.31% of the fallopian tube cancer market size by 2025. Surgery and platinum-based chemotherapy remained the foundation of initial management, while targeted therapy and immunotherapy were used in maintenance or recurrent settings. The diagnosis sub-segment is forecast to grow at a CAGR of 8.88% from 2026 to 2031. Molecular and genomic testing are becoming prerequisites for patients who may receive targeted therapies. The fallopian tube cancer industry is therefore seeing a larger role for testing before treatment decisions are made.

Antibody-drug conjugates and targeted therapies are changing the treatment mix even while chemotherapy retains the greatest treatment volume. NCCN materials include a Category 2B recommendation for trastuzumab deruxtecan in HER2-positive platinum-sensitive ovarian cancer, providing a clinical framework relevant to fallopian tube cancer. Germline and somatic testing are increasingly used alongside comprehensive genomic profiling. Imaging with MRI and PET remains relevant for presurgical staging. A 2025 case report found that transvaginal sonography identified an early-stage fallopian tube carcinosarcoma that enhanced CT had missed. The connection between therapeutic approvals and required companion diagnostics supports the faster growth of diagnosis in the fallopian tube cancer market.

Stage I accounted for 45.24% of the fallopian tube cancer market share by disease stage in 2025. Its position reflects the number of surgically managed patients whose disease can be addressed with cytoreductive surgery. Earlier diagnosis can be prompted by watery vaginal discharge associated with the hydrops tubae profluens triad. Stage II is forecast to expand at a CAGR of 9.22% from 2026 to 2031. Reclassification of high-grade serous tumors to a fallopian tube origin increases recognition of Stage II cases that may previously have been coded as advanced ovarian cancer.

Perioperative chemotherapy is also being used more often in Stage II disease. Stage III remains the most treatment-intensive stage because patients commonly need combination regimens and maintenance PARP inhibitor therapy. Stage IV has the lowest incidence but can generate high per-patient treatment costs because of salvage regimens and antibody-drug conjugate protocols. The evidence base still draws heavily on FIGO systems originally developed for ovarian carcinoma. This shared framework helps clinicians classify disease, but restricts stage-specific natural history data for primary fallopian tube carcinoma. Updated FIGO criteria apply to a unified ovarian, fallopian tube, and peritoneal classification, which affects how the fallopian tube cancer market is tracked by stage.

Complete Report Scope:

• By Offering
  • By Treatment Type
    • Surgery
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy
    • Hormonal Therapy
    • Radiation Therapy
    • Combination Regimens
  • By Diagnosis
    • Ultrasound
    • Computed Tomography
    • Magnetic Resonance Imaging
    • Positron Emission Tomography
    • Biopsy and Histopathology
    • CA-125 Blood Testing
    • Germline and Somatic Genetic Testing
    • Comprehensive Genomic Profiling
• By Disease Stage
  • Stage I
  • Stage II
  • Stage III
  • Stage IV
• By Histology
  • High-Grade Serous Carcinoma
  • Low-Grade Serous Carcinoma
  • Endometrioid Carcinoma
  • Clear Cell Carcinoma
  • Mucinous Carcinoma
  • Carcinosarcoma
• By End User
  • Hospitals
  • Cancer Specialty Centers
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of the global fallopian tube cancer market share in 2025. The region benefits from established regulation, high per-patient treatment spending, and extensive clinical trial activity. The United States remains the largest national setting because the FDA approved mirvetuximab soravtansine in March 2024, and CMS Quality Measure #507 supports genetic testing within 6 months of diagnosis. ASCO guidance and NCCN frameworks support multigene workup at diagnosis. Mexico remains less developed because formulary delays and lower oncology spending limit access to the biomarker-guided therapy and PARP inhibitors.

Europe follows North America in absolute contribution to the fallopian tube cancer market, with Germany, the United Kingdom, and France accounting for the largest national shares. The CHMP delivered a positive opinion on mirvetuximab soravtansine in September 2024, supporting potential EU-wide access. NICE recommended niraparib for routine NHS use in February 2026 after first-line platinum-based chemotherapy for advanced fallopian tube cancer. Asia-Pacific is the fastest-growing regional part of the fallopian tube cancer market, with a projected CAGR of 9.25% from 2026 to 2031. India, China, South Korea, and the Philippines are increasing oncology capacity, while China’s drug approval acceleration and reimbursement inclusion remain important near-term factors.

Middle East and Africa and South America are smaller but relevant parts of the fallopian tube cancer market. GCC countries and Brazil account for a disproportionate share of oncology spending within their regions. Cancer registries and private oncology networks are expanding in the GCC, although the absence of population-wide screening means many patients still present at Stage III or Stage IV. South Africa has the most developed oncology setting in Africa, but pathology capacity constrains timely molecular testing and accurate histological subtyping. Brazil is relevant to maintenance PARP inhibitor adoption because GSK began a Phase IV niraparib study there within its wider program. Argentina and the rest of South America remain behind on diagnostic infrastructure, but are improving access to platinum-based chemotherapy through public procurement programs.

List of Companies Covered in this Report:

• Abbvie
• Amgen
• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Daiichi Sankyo
• Eisai
• Eli Lilly and Company
• Roche
• Genmab
• GlaxoSmithKline
• Illumina
• ImmunoGen, Inc.
• Johnson & Johnson
• Merck
• Mersana Therapeutics, Inc.
• Myriad Genetics
• Novartis
• Pfizer

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support